Attitudes of Care Partners Toward Medications for Parkinson’s Disease Psychosis
Objective: To explore attitudes regarding use of medications among care partners of individuals with Parkinson’s disease psychosis. Background: Parkinson’s disease (PD) psychosis is a highly…CVT-301 treatment provides consistent and clinically significant improvements in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) over 12 weeks
Objective: A post hoc analysis of UPDRS-III sequential changes over the 12-week treatment period of a phase 3 study. Background: CVT-301 is an inhaled levodopa…Parkinson Progression Marker Initiative 2.0 – New Science/New Cohorts
Objective: The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes,…Phase I Study Design of a Leucine-Rich Repeat Kinase 2 (LRRK2) Antisense Oligonucleotide, for Parkinson’s Disease
Objective: We will present the preclinical efficacy and safety data and the design of the first in human trial of an antisense oligonucleotide (ASO) for…Spontaneous smoking cessation in a parkinsonian patient treated with apomorphine pump
Objective: To describe the case of a parkinsonian patient treated by apomorphine pump who stopped smoking without difficulty despite being dependent to nicotine. To explore…Comparing the effects of rosemary and selegiline on behavioral symptoms of Parkinson’s animal model in mice
Objective: Parkinson is from common disorders of central nervous system and the second disease in neurodegenerative diseases which occurs in 1% of people over the…Characterization of novel alpha-synuclein aggregation model of Parkinson’s disease
Objective: To establish and characterize a robust alpha-synuclein (aSyn) aggregation pathology research model to allow efficient drug development platform for Parkinson's disease (PD). Background: PD…Decline in the midbrain-to-pons ratio over one year can support the differentiation between PSP and IPD
Objective: The midbrain-to-pons ratio (MTPR) is considered as an important diagnostic biomarker to differentiate between progressive supranuclear palsy (PSP) and idiopathic Parkinson’s disease (IPD). Here,…May Safinamide have a Role in Atypical Parkinsonism? A Retrospective Study in Clinical Practice
Objective: To evaluate efficacy and safety of safinamide in atypical parkinsonian syndromes. Background: Safinamide (50-100 mg) has proved efficacy as an add-on treatment to levodopa…Predictors of Falls with Injuries in People with Parkinson’s Disease
Objective: To identify predictors of falls with injuries in people with Parkinson’s disease (PD). Background: Falls are common in people with PD and can lead…
- « Previous Page
- 1
- …
- 147
- 148
- 149
- 150
- 151
- …
- 425
- Next Page »